[go: up one dir, main page]

WO2008149563A1 - Function-selective vitamin d receptor agonist - Google Patents

Function-selective vitamin d receptor agonist Download PDF

Info

Publication number
WO2008149563A1
WO2008149563A1 PCT/JP2008/050027 JP2008050027W WO2008149563A1 WO 2008149563 A1 WO2008149563 A1 WO 2008149563A1 JP 2008050027 W JP2008050027 W JP 2008050027W WO 2008149563 A1 WO2008149563 A1 WO 2008149563A1
Authority
WO
WIPO (PCT)
Prior art keywords
function
receptor agonist
vitamin
selective vitamin
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/050027
Other languages
French (fr)
Japanese (ja)
Inventor
Makoto Makishima
Michiyasu Ishizawa
Manabu Matsunawa
Sachiko Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nihon University
Original Assignee
Nihon University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon University filed Critical Nihon University
Priority to JP2009517731A priority Critical patent/JP5283043B2/en
Priority to EP08702908.8A priority patent/EP2163557B1/en
Priority to US12/601,998 priority patent/US9278992B2/en
Publication of WO2008149563A1 publication Critical patent/WO2008149563A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

It is intended to provide a VDR ligand which does not induce hypercalcemia that is the side effect of a vitamin D3 preparation. A composition which contains lithocholic acid propionate, its salt or a solvate or prodrug of the same.
PCT/JP2008/050027 2007-06-04 2008-01-07 Function-selective vitamin d receptor agonist Ceased WO2008149563A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2009517731A JP5283043B2 (en) 2007-06-04 2008-01-07 Action-selective vitamin D receptor agonist
EP08702908.8A EP2163557B1 (en) 2007-06-04 2008-01-07 Function-selective vitamin d receptor agonist
US12/601,998 US9278992B2 (en) 2007-06-04 2008-01-07 Function-selective vitamin D receptor agonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007147866 2007-06-04
JP2007-147866 2007-06-04

Publications (1)

Publication Number Publication Date
WO2008149563A1 true WO2008149563A1 (en) 2008-12-11

Family

ID=40093393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/050027 Ceased WO2008149563A1 (en) 2007-06-04 2008-01-07 Function-selective vitamin d receptor agonist

Country Status (4)

Country Link
US (1) US9278992B2 (en)
EP (1) EP2163557B1 (en)
JP (1) JP5283043B2 (en)
WO (1) WO2008149563A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017131144A1 (en) * 2016-01-28 2017-08-03 国立大学法人お茶の水女子大学 Lithocholic acid derivative having vitamin d activity
CN114686450A (en) * 2020-12-28 2022-07-01 苏州引航生物科技有限公司 Modified vitamin D hydroxylase mutant and application thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356006B (en) * 2013-10-18 2018-04-24 Centro De Investig Y Asistencia En Tecnologia Y Diseno Del Estado De Jalisco A C Process for obtaining a molecule serving as an antimicrobial peptide elicitor.
PL3768274T3 (en) * 2018-03-19 2024-06-17 Epicyt Pharma Ab COMPOSITIONS CONTAINING A COMBINATION OF GLYCOCHOLIC ACID AND BUTARY ACID OR OLEIC ACID FOR USE IN THE TREATMENT OF OSTEOPOROSIS
CN116159068A (en) * 2021-11-25 2023-05-26 香港理工大学深圳研究院 Novel use of bile acids and/or bile acid receptor agonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007147866A (en) 2005-11-25 2007-06-14 Sony Corp Self-luminous display device, light emission condition control device, light emission condition control method, and program

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846411A (en) * 1971-08-04 1974-11-05 Medichemie Ag Choleretically active esters and salts of bile acids

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007147866A (en) 2005-11-25 2007-06-14 Sony Corp Self-luminous display device, light emission condition control device, light emission condition control method, and program

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ADACHI, R. ET AL.: "Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative", JOURNAL OF LIPID RESEARCH, vol. 46, 2005, pages 46 - 57, XP008116081 *
ISHIZAWA, M. ET AL.: "Lithocholic acid derivatives act as selective vitamin D receptor modulators", J LIPID RES, 7 January 2008 (2008-01-07), XP008116082, Retrieved from the Internet <URL:http://www.jlr.org/cgi/ reprint/M700293-J> [retrieved on 20080311] *
MAKISHIMA, M. ET AL.: "Vitamin D Receptor As an Intestinal Bile Acid Sensor", SCIENCE, vol. 296, 17 May 2002 (2002-05-17), pages 1313 - 1316, XP008116080 *
NAGPAL, S. ET AL.: "Noncalcemic actions of vitamin D receptor ligands", ENDOCRINE REVIEWS, vol. 26, no. 5, 2005, pages 662 - 687, XP003020911 *
See also references of EP2163557A4 *
SHAIKH ET AL.: "Synthesis and mesomorphic behaviour of lithocholic acid derivatives", BULLETIN OF MATERIAL SCIENCE, vol. 26, no. 5, 2003, pages 559 - 563, XP008116077 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017131144A1 (en) * 2016-01-28 2017-08-03 国立大学法人お茶の水女子大学 Lithocholic acid derivative having vitamin d activity
CN114686450A (en) * 2020-12-28 2022-07-01 苏州引航生物科技有限公司 Modified vitamin D hydroxylase mutant and application thereof
CN114686450B (en) * 2020-12-28 2024-04-16 苏州引航生物科技有限公司 Modified vitamin D hydroxylase mutants and uses thereof

Also Published As

Publication number Publication date
EP2163557A1 (en) 2010-03-17
US9278992B2 (en) 2016-03-08
JPWO2008149563A1 (en) 2010-08-19
US20100204191A1 (en) 2010-08-12
EP2163557A4 (en) 2011-06-22
JP5283043B2 (en) 2013-09-04
EP2163557B1 (en) 2014-10-15

Similar Documents

Publication Publication Date Title
WO2009057104A3 (en) Polymer-based fire-retarding formulations
AU2007299727A8 (en) Self preserved aqueous pharmaceutical compositions
IL202103A0 (en) Controlled release pharmaceutical compositions for prolonged effect
WO2010138598A3 (en) Lxr modulators
PL2004636T3 (en) Substituted enaminocarbonyl compounds used as insecticides
WO2010036407A3 (en) Antiviral nucleoside analogs
IL213583A0 (en) Solid compositions containing the ingredient rasagiline
GB2464430A8 (en) Emulsion compositions
IL194917A0 (en) Co-extruded compositions for high aspect ratio structures
WO2012042371A3 (en) Pharmaceutical composition
EP2416806B8 (en) Fucoidans as ligands for the diagnosis of degenerative pathologies
WO2011154725A3 (en) Compositions comprising buprenorphine
GB0800991D0 (en) Emulsion for use as confectionery filling
WO2012106665A3 (en) Disialyllacto-n-tetraose (dslnt) or variants, isomers, analogs and derivatives thereof to prevent or inhibit bowel disease
WO2012137227A3 (en) Solid forms of antiretroviral compounds and anti-oxidative acids, processes for preparation and pharmaceutical compositions thereof
WO2008149563A1 (en) Function-selective vitamin d receptor agonist
ZA200902467B (en) Stabilized prostaglandin E composition
EP2188357A4 (en) Vegetal oil derivatives plasticizers
EP2262536A4 (en) Stabilizing lipid compositions for oral pharmaceutical agents
WO2011014003A3 (en) (+)-3-hydroxymorphinan derivatives as neuroprotectants
IL173791A0 (en) Improved stabilization for flight platforms
CA2865491A1 (en) Spray dried formulations
WO2009003001A3 (en) Preparation of risedronate sodium hemi-pentahydrate
AU2019903639A0 (en) Improvements relating to void platforms
AU2019901745A0 (en) Improvements relating to void platforms

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08702908

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009517731

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008702908

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12601998

Country of ref document: US